AxoGen Statistics
Total Valuation
AxoGen has a market cap or net worth of $398.59 million. The enterprise value is $447.02 million.
| Market Cap | 398.59M |
| Enterprise Value | 447.02M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AxoGen has 43.70 million shares outstanding. The number of shares has increased by 1.56% in one year.
| Shares Outstanding | 43.70M |
| Shares Change (YoY) | +1.56% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 5.19% |
| Owned by Institutions (%) | 81.32% |
| Float | 33.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.43 |
| Forward PS | 2.12 |
| PB Ratio | 4.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.77.
| Current Ratio | 3.43 |
| Quick Ratio | 2.09 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.14 |
Financial Efficiency
Return on equity (ROE) is -22.20% and return on invested capital (ROIC) is -11.31%.
| Return on Equity (ROE) | -22.20% |
| Return on Assets (ROA) | -11.10% |
| Return on Capital (ROIC) | -11.31% |
| Revenue Per Employee | $382,537 |
| Profits Per Employee | -$49,713 |
| Employee Count | 428 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 1.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.70% in the last 52 weeks. The beta is 1.11, so AxoGen's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +2.70% |
| 50-Day Moving Average | 7.16 |
| 200-Day Moving Average | 7.19 |
| Relative Strength Index (RSI) | 68.35 |
| Average Volume (20 Days) | 377,004 |
Short Selling Information
The latest short interest is 2.15 million, so 4.92% of the outstanding shares have been sold short.
| Short Interest | 2.15M |
| Short Previous Month | 1.92M |
| Short % of Shares Out | 4.92% |
| Short % of Float | 6.36% |
| Short Ratio (days to cover) | 5.37 |
Income Statement
In the last 12 months, AxoGen had revenue of $163.73 million and -$21.28 million in losses. Loss per share was -$0.50.
| Revenue | 163.73M |
| Gross Profit | 130.54M |
| Operating Income | -18.68M |
| Pretax Income | -21.28M |
| Net Income | -21.28M |
| EBITDA | -9.93M |
| EBIT | -16.13M |
| Loss Per Share | -$0.50 |
Balance Sheet
The company has $23.63 million in cash and $72.07 million in debt, giving a net cash position of -$48.44 million or -$1.11 per share.
| Cash & Cash Equivalents | 23.63M |
| Total Debt | 72.07M |
| Net Cash | -48.44M |
| Net Cash Per Share | -$1.11 |
| Equity (Book Value) | 93.16M |
| Book Value Per Share | 2.13 |
| Working Capital | 55.73M |
Cash Flow
In the last 12 months, operating cash flow was -$10.56 million and capital expenditures -$10.49 million, giving a free cash flow of -$21.05 million.
| Operating Cash Flow | -10.56M |
| Capital Expenditures | -10.49M |
| Free Cash Flow | -21.05M |
| FCF Per Share | -$0.49 |
Margins
Gross margin is 79.73%, with operating and profit margins of -11.41% and -13.00%.
| Gross Margin | 79.73% |
| Operating Margin | -11.41% |
| Pretax Margin | -13.00% |
| Profit Margin | -13.00% |
| EBITDA Margin | -6.06% |
| EBIT Margin | -9.85% |
| FCF Margin | -12.86% |
Dividends & Yields
AxoGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.56% |
| Shareholder Yield | -1.56% |
| Earnings Yield | -5.34% |
| FCF Yield | -5.28% |
Analyst Forecast
The average price target for AxoGen is $13.00, which is 42.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 42.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 13.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 11, 1994. It was a forward split with a ratio of 105:100.
| Last Split Date | Jul 11, 1994 |
| Split Type | Forward |
| Split Ratio | 105:100 |
Scores
AxoGen has an Altman Z-Score of 1.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.35 |
| Piotroski F-Score | 3 |